ophthalmology

horse horse riding lasso man on horse in shadows

Biotech

Ollin hauls in $330M for Vabysmo challenger's ph. 3 gauntlet

Two trials will focus on the lead indication of diabetic macular edema, where OLN324 topped Vabysmo in an earlier phase 1b trial.

Darren Incorvaia Jun 24, 2026 7:00am

eyeball eye disease eyelash eyes

Ocugen’s CEO wants to bring gene therapy to the masses

Apr 16, 2026 9:00am

Closeup of blue eye on black background

Viridian’s Tepezza rival scores ph. 3 win, but investors unsure

Mar 30, 2026 10:11am

Closeup of blue eye on black background

Innovent eyes China approval after matching Eylea in phase 3

Mar 24, 2026 6:00am

Closeup of blue eye on black background

Kalaris pauses eye drug trial to resolve ocular inflammation

Mar 11, 2026 6:30am

Closeup of blue eye on black background

Preclinical eye disease biotech sets sights on $17M NYSE IPO

Feb 18, 2026 8:55am